Last reviewed · How we verify
Investigational TIV-HD2
TIV-HD2 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against seasonal influenza.
TIV-HD2 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against seasonal influenza. Used for Prevention of seasonal influenza in adults, particularly elderly or immunocompromised populations.
At a glance
| Generic name | Investigational TIV-HD2 |
|---|---|
| Also known as | High-dose trivalent influenza vaccine (alternate B strain) |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
TIV-HD2 contains higher antigen content compared to standard-dose influenza vaccines, intended to elicit a stronger and more durable immune response. This formulation is particularly targeted at improving vaccine efficacy in populations with reduced immune responsiveness, such as elderly individuals or immunocompromised patients.
Approved indications
- Prevention of seasonal influenza in adults, particularly elderly or immunocompromised populations
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US (PHASE3)
- A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational TIV-HD2 CI brief — competitive landscape report
- Investigational TIV-HD2 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI